August 11, 2020
Add to Twitter
English | عربي
 
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
- Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction

- Treatment of heart failure is an important unmet need with over half of those diagnosed dying within five years1
 
News Agencies Feed